Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original human data
PubMed 41753348 · doi:10.3390/jcm15041661
What was done
The authors synthesized literature examining the pathophysiology, clinical overlap, and bidirectional relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia (both primary age-related and secondary metabolic sarcopenia).
What was found
The abstract provides no numbers or quantitative metrics. It reports qualitative associations: skeletal muscle is the primary site of insulin-stimulated glucose disposal, and sarcopenia, muscle fatty degeneration, liver fibrosis, and insulin resistance strongly correlate in a bidirectional vicious cycle in MASLD.
Why it matters
Recognizing the mutual interaction between muscle loss and metabolic liver disease highlights sarcopenia as an important clinical consideration alongside liver fibrosis in managing MASLD.
Limits
This is a narrative review with no original human data, search protocol, or meta-analytic pooling. The abstract lacks quantitative effect estimates, sample size counts, and specific diagnostic criteria.
Cited by
- supports Skeletal muscle is the primary site where the human body clears glucose from the bloodstream.